Abemaciclib works by inhibiting the activity of CDK4 and CDK6, which are involved in the progression of the cell cycle from the G1 phase to the S phase. By blocking these enzymes, abemaciclib effectively halts the proliferation of cancer cells, slowing down tumor growth. This mechanism makes it particularly effective in cancers that are driven by the overactivity of these kinases.
